Literature DB >> 31147612

The next generation of CRISPR-Cas technologies and applications.

Adrian Pickar-Oliver1,2, Charles A Gersbach3,4,5.   

Abstract

The prokaryote-derived CRISPR-Cas genome editing systems have transformed our ability to manipulate, detect, image and annotate specific DNA and RNA sequences in living cells of diverse species. The ease of use and robustness of this technology have revolutionized genome editing for research ranging from fundamental science to translational medicine. Initial successes have inspired efforts to discover new systems for targeting and manipulating nucleic acids, including those from Cas9, Cas12, Cascade and Cas13 orthologues. Genome editing by CRISPR-Cas can utilize non-homologous end joining and homology-directed repair for DNA repair, as well as single-base editing enzymes. In addition to targeting DNA, CRISPR-Cas-based RNA-targeting tools are being developed for research, medicine and diagnostics. Nuclease-inactive and RNA-targeting Cas proteins have been fused to a plethora of effector proteins to regulate gene expression, epigenetic modifications and chromatin interactions. Collectively, the new advances are considerably improving our understanding of biological processes and are propelling CRISPR-Cas-based tools towards clinical use in gene and cell therapies.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31147612      PMCID: PMC7079207          DOI: 10.1038/s41580-019-0131-5

Source DB:  PubMed          Journal:  Nat Rev Mol Cell Biol        ISSN: 1471-0072            Impact factor:   94.444


  248 in total

1.  Efficient isolation of specific genomic regions and identification of associated proteins by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) using CRISPR.

Authors:  Toshitsugu Fujita; Hodaka Fujii
Journal:  Biochem Biophys Res Commun       Date:  2013-08-11       Impact factor: 3.575

2.  Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9.

Authors:  Gozde Korkmaz; Rui Lopes; Alejandro P Ugalde; Ekaterina Nevedomskaya; Ruiqi Han; Ksenia Myacheva; Wilbert Zwart; Ran Elkon; Reuven Agami
Journal:  Nat Biotechnol       Date:  2016-01-11       Impact factor: 54.908

Review 3.  Functions and regulation of RNA editing by ADAR deaminases.

Authors:  Kazuko Nishikura
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

4.  Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.

Authors:  Dominik Paquet; Dylan Kwart; Antonia Chen; Andrew Sproul; Samson Jacob; Shaun Teo; Kimberly Moore Olsen; Andrew Gregg; Scott Noggle; Marc Tessier-Lavigne
Journal:  Nature       Date:  2016-04-27       Impact factor: 49.962

5.  Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.

Authors:  Qiurong Ding; Alanna Strong; Kevin M Patel; Sze-Ling Ng; Bridget S Gosis; Stephanie N Regan; Chad A Cowan; Daniel J Rader; Kiran Musunuru
Journal:  Circ Res       Date:  2014-06-10       Impact factor: 17.367

6.  Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10.

Authors:  Morgan L Maeder; Michael Stefanidakis; Christopher J Wilson; Reshica Baral; Luis Alberto Barrera; George S Bounoutas; David Bumcrot; Hoson Chao; Dawn M Ciulla; Jennifer A DaSilva; Abhishek Dass; Vidya Dhanapal; Tim J Fennell; Ari E Friedland; Georgia Giannoukos; Sebastian W Gloskowski; Alexandra Glucksmann; Gregory M Gotta; Hariharan Jayaram; Scott J Haskett; Bei Hopkins; Joy E Horng; Shivangi Joshi; Eugenio Marco; Rina Mepani; Deepak Reyon; Terence Ta; Diana G Tabbaa; Steven J Samuelsson; Shen Shen; Maxwell N Skor; Pam Stetkiewicz; Tongyao Wang; Clifford Yudkoff; Vic E Myer; Charles F Albright; Haiyan Jiang
Journal:  Nat Med       Date:  2019-01-21       Impact factor: 53.440

7.  Manipulation of nuclear architecture through CRISPR-mediated chromosomal looping.

Authors:  Stefanie L Morgan; Natasha C Mariano; Abel Bermudez; Nicole L Arruda; Fangting Wu; Yunhai Luo; Gautam Shankar; Lin Jia; Huiling Chen; Ji-Fan Hu; Andrew R Hoffman; Chiao-Chain Huang; Sharon J Pitteri; Kevin C Wang
Journal:  Nat Commun       Date:  2017-07-13       Impact factor: 14.919

8.  An enhanced CRISPR repressor for targeted mammalian gene regulation.

Authors:  Nan Cher Yeo; Alejandro Chavez; Alissa Lance-Byrne; Yingleong Chan; David Menn; Denitsa Milanova; Chih-Chung Kuo; Xiaoge Guo; Sumana Sharma; Angela Tung; Ryan J Cecchi; Marcelle Tuttle; Swechchha Pradhan; Elaine T Lim; Noah Davidsohn; Mo R Ebrahimkhani; James J Collins; Nathan E Lewis; Samira Kiani; George M Church
Journal:  Nat Methods       Date:  2018-07-16       Impact factor: 28.547

9.  CRISPR RNA-guided activation of endogenous human genes.

Authors:  Morgan L Maeder; Samantha J Linder; Vincent M Cascio; Yanfang Fu; Quan H Ho; J Keith Joung
Journal:  Nat Methods       Date:  2013-07-25       Impact factor: 28.547

10.  Functional footprinting of regulatory DNA.

Authors:  Jeff Vierstra; Andreas Reik; Kai-Hsin Chang; Sandra Stehling-Sun; Yuanyue Zhou; Sarah J Hinkley; David E Paschon; Lei Zhang; Nikoletta Psatha; Yuri R Bendana; Colleen M O'Neil; Alexander H Song; Andrea K Mich; Pei-Qi Liu; Gary Lee; Daniel E Bauer; Michael C Holmes; Stuart H Orkin; Thalia Papayannopoulou; George Stamatoyannopoulos; Edward J Rebar; Philip D Gregory; Fyodor D Urnov; John A Stamatoyannopoulos
Journal:  Nat Methods       Date:  2015-08-31       Impact factor: 28.547

View more
  278 in total

1.  Is microfluidics the "assembly line" for CRISPR-Cas9 gene-editing?

Authors:  Fatemeh Ahmadi; Angela B V Quach; Steve C C Shih
Journal:  Biomicrofluidics       Date:  2020-11-24       Impact factor: 2.800

Review 2.  CRISPR technologies for precise epigenome editing.

Authors:  Muneaki Nakamura; Yuchen Gao; Antonia A Dominguez; Lei S Qi
Journal:  Nat Cell Biol       Date:  2021-01-08       Impact factor: 28.824

3.  Synthetic Biology-Empowered Hydrogels for Medical Diagnostics.

Authors:  Hanna J Wagner; Hasti Mohsenin; Wilfried Weber
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 4.  CRISPR, Prime Editing, Optogenetics, and DREADDs: New Therapeutic Approaches Provided by Emerging Technologies in the Treatment of Spinal Cord Injury.

Authors:  Vera Paschon; Felipe Fernandes Correia; Beatriz Cintra Morena; Victor Allisson da Silva; Gustavo Bispo Dos Santos; Maria Cristina Carlan da Silva; Alexandre Fogaça Cristante; Stephanie Michelle Willerth; Florence Evelyne Perrin; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2020-01-11       Impact factor: 5.590

Review 5.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

6.  A CRISPR-Cas9, Cre-lox, and Flp-FRT Cascade Strategy for the Precise and Efficient Integration of Exogenous DNA into Cellular Genomes.

Authors:  Jixue Li; Yanjie Li; Kevin M Pawlik; Jill S Napierala; Marek Napierala
Journal:  CRISPR J       Date:  2020-11-03

Review 7.  Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors.

Authors:  Paul Boucher; Xiaoxia Cui; David T Curiel
Journal:  J Control Release       Date:  2020-09-03       Impact factor: 9.776

Review 8.  Clonal expansion in non-cancer tissues.

Authors:  Nobuyuki Kakiuchi; Seishi Ogawa
Journal:  Nat Rev Cancer       Date:  2021-02-24       Impact factor: 60.716

9.  PAM recognition by miniature CRISPR-Cas12f nucleases triggers programmable double-stranded DNA target cleavage.

Authors:  Tautvydas Karvelis; Greta Bigelyte; Joshua K Young; Zhenglin Hou; Rimante Zedaveinyte; Karolina Budre; Sushmitha Paulraj; Vesna Djukanovic; Stephen Gasior; Arunas Silanskas; Česlovas Venclovas; Virginijus Siksnys
Journal:  Nucleic Acids Res       Date:  2020-05-21       Impact factor: 16.971

Review 10.  Fighting Persistence: How Chronic Infections with Mycobacterium tuberculosis Evade T Cell-Mediated Clearance and New Strategies To Defeat Them.

Authors:  Laurisa Ankley; Sean Thomas; Andrew J Olive
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.